- Home
- CAPT vs AVTX Comparison
CAPT vs AVTX Comparison
Compare CAPT & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAPT
- AVTX
- Stock Information
- Founded
- CAPT 2005
- AVTX 2011
- Country
- CAPT South Korea
- AVTX United States
- Employees
- CAPT N/A
- AVTX N/A
- Industry
- CAPT Blank Checks
- AVTX Biotechnology: Pharmaceutical Preparations
- Sector
- CAPT Finance
- AVTX Health Care
- Exchange
- CAPT Nasdaq
- AVTX Nasdaq
- Market Cap
- CAPT 54.4M
- AVTX 57.4M
- IPO Year
- CAPT N/A
- AVTX 2015
- Fundamental
- Price
- CAPT $1.25
- AVTX $7.89
- Analyst Decision
- CAPT
- AVTX Strong Buy
- Analyst Count
- CAPT 0
- AVTX 7
- Target Price
- CAPT N/A
- AVTX $31.00
- AVG Volume (30 Days)
- CAPT 478.8K
- AVTX 149.3K
- Earning Date
- CAPT 01-01-0001
- AVTX 08-11-2025
- Dividend Yield
- CAPT N/A
- AVTX N/A
- EPS Growth
- CAPT N/A
- AVTX N/A
- EPS
- CAPT N/A
- AVTX N/A
- Revenue
- CAPT $17,389,944.00
- AVTX $441,000.00
- Revenue This Year
- CAPT N/A
- AVTX N/A
- Revenue Next Year
- CAPT N/A
- AVTX N/A
- P/E Ratio
- CAPT N/A
- AVTX $1.17
- Revenue Growth
- CAPT 84.70
- AVTX N/A
- 52 Week Low
- CAPT $0.37
- AVTX $3.39
- 52 Week High
- CAPT $2.60
- AVTX $16.00
- Technical
- Relative Strength Index (RSI)
- CAPT 43.15
- AVTX 80.64
- Support Level
- CAPT $1.45
- AVTX $6.21
- Resistance Level
- CAPT $1.57
- AVTX $6.89
- Average True Range (ATR)
- CAPT 0.13
- AVTX 0.64
- MACD
- CAPT -0.05
- AVTX 0.17
- Stochastic Oscillator
- CAPT 2.16
- AVTX 78.59
About CAPT Captivision Inc.
Captivision Inc Formerly Glaam Co Ltd is engaged in manufacturing, installing, and selling LED display G-Glass. G-Glass is an integrated ICT product that has the basic characteristics of transparent glass but can display media images at the same time. It implements media images through the glass surface while preserving the features of clear and transparent glass. G-Glass is the world's first IT building material that can be applied to various places where glass is used.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).